Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations

Azeem Latib, John Cosgrave, Cosmo Godino, Asif Qasim, Simon J. Corbett, Davide Tavano, Nuccia Morici, Nicole Cristell, Alaide Chieffo, Mauro Carlino, Matteo Montorfano, Flavio Airoldi, Antonio Colombo

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Background: The aim of the study was to compare the outcomes of sirolimus-eluting (SES) and paclitaxel-eluting (PES) stent implantation in coronary bifurcations treated with either a 1-stent or 2-stent strategy. Methods: The study used a retrospective cohort analysis of consecutive de novo bifurcations, excluding left main, treated with SES or PES between April 2003 and June 2005. Results: We identified 170 bifurcations in 161 patients treated with SES and 119 bifurcations in 112 patients treated with PES. During a median follow-up of 1,061 days (interquartile range 814-1,314), 43 patients (26.7%) in the SES group and 28 (25.0%) in the PES group had a major adverse cardiac event (P = .78). The angiographic restenosis rate per bifurcation was 20.9% and 25.9%, respectively (P = .41). There was no difference overall in the occurrence of target lesion revascularization (TLR) per bifurcation, 22 with SES (12.9%) and 18 with PES (15.1%), P = .61. The TLR rate was similar for SES and PES in bifurcations treated with 1 stent (6.7% vs 11.4%, P = .40) and in bifurcations treated with both branch stenting (20.0% vs 20.4%, P =1.0). Conclusions: In this cohort, the long-term clinical outcomes appear similar overall between SES and PES in the treatment of coronary bifurcations irrespective of whether a 1-stent or 2-stent strategy was used.

Original languageEnglish (US)
Pages (from-to)745-750
Number of pages6
JournalAmerican heart journal
Volume156
Issue number4
DOIs
StatePublished - Oct 2008
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Sirolimus-eluting and paclitaxel-eluting stents for the treatment of coronary bifurcations'. Together they form a unique fingerprint.

Cite this